XML 49 R32.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment, Geographic and Other Revenue Information (Tables) | 9 Months Ended
--- | ---
Oct. 01, 2017
Segment Reporting [Abstract] |
Reconciliation of Revenue from Segments to Consolidated |
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | October 1, 2017 |  |  | October 2, 2016 |
Reportable Segments: |  |  |  |  |  |  |  |
IH |  | $ | 8,118 |  |  | $ | 7,332 |  |  | $ | 4,875 |  |  | $ | 4,187 |
EH |  | 5,050 |  |  | 5,712 |  |  | 2,765 |  |  | 3,128 |
Total reportable segments |  | 13,168 |  |  | 13,045 |  |  | 7,640 |  |  | 7,315 |
Other business activities(b), (c) |  | — |  |  | — |  |  | (759 | ) |  | (753 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate(c) |  | — |  |  | — |  |  | (1,382 | ) |  | (1,537 | )
Purchase accounting adjustments(c) |  | — |  |  | — |  |  | (1,154 | ) |  | (966 | )
Acquisition-related costs(c) |  | — |  |  | — |  |  | (155 | ) |  | (280 | )
Certain significant items(d) |  | — |  |  | — |  |  | (449 | ) |  | (1,969 | )
Other unallocated |  | — |  |  | — |  |  | (156 | ) |  | (206 | )
|  | $ | 13,168 |  |  | $ | 13,045 |  |  | $ | 3,585 |  |  | $ | 1,604 |
|  | Nine Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | October 1, 2017 |  |  | October 2, 2016 |
Reportable Segments: |  |  |  |  |  |  |  |
IH |  | $ | 23,204 |  |  | $ | 21,471 |  |  | $ | 14,190 |  |  | $ | 12,470 |
EH |  | 15,639 |  |  | 17,725 |  |  | 8,558 |  |  | 9,985 |
Total reportable segments |  | 38,843 |  |  | 39,196 |  |  | 22,748 |  |  | 22,454 |
Other business activities(b), (c) |  | — |  |  | — |  |  | (2,205 | ) |  | (2,096 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate(c) |  | — |  |  | — |  |  | (3,948 | ) |  | (4,217 | )
Purchase accounting adjustments(c) |  | — |  |  | — |  |  | (3,527 | ) |  | (3,103 | )
Acquisition-related costs(c) |  | — |  |  | — |  |  | (347 | ) |  | (598 | )
Certain significant items(d) |  | — |  |  | — |  |  | (797 | ) |  | (4,112 | )
Other unallocated |  | — |  |  | — |  |  | (573 | ) |  | (753 | )
|  | $ | 38,843 |  |  | $ | 39,196 |  |  | $ | 11,351 |  |  | $ | 7,575 |
(a) | Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million, respectively, from our investment in ViiV. For additional information, see Note 4.
(b) | Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $33 million and $94 million of costs from Other Business Activities to Corporate in the third quarter and first nine months of 2016, respectively, to conform to the current period presentation.
(c) | For a description, see the “Other Costs and Business Activities” section above.
(d) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in the third quarter of 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $90 million, (ii) charges for certain legal matters of $183 million, (iii) income of $12 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $45 million. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million, (ii) income for certain legal matters of $40 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion, (iv) certain asset impairment charges of $126 million, (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million. For additional information, see Note 3 and Note 4. For Earnings in the first nine months of 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $253 million, (ii) charges for certain legal matters of $191 million, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $52 million, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $54 million and (vi) other charges of $119 million. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million, (ii) charges for certain legal matters of $506 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion, (iv) certain asset impairment charges of $1.1 billion, (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million. For additional information, see Note 3 and Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | October 1, 2017 |  |  | October 2, 2016 |
Reportable Segments: |  |  |  |  |  |  |  |
IH |  | $ | 8,118 |  |  | $ | 7,332 |  |  | $ | 4,875 |  |  | $ | 4,187 |
EH |  | 5,050 |  |  | 5,712 |  |  | 2,765 |  |  | 3,128 |
Total reportable segments |  | 13,168 |  |  | 13,045 |  |  | 7,640 |  |  | 7,315 |
Other business activities(b), (c) |  | — |  |  | — |  |  | (759 | ) |  | (753 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate(c) |  | — |  |  | — |  |  | (1,382 | ) |  | (1,537 | )
Purchase accounting adjustments(c) |  | — |  |  | — |  |  | (1,154 | ) |  | (966 | )
Acquisition-related costs(c) |  | — |  |  | — |  |  | (155 | ) |  | (280 | )
Certain significant items(d) |  | — |  |  | — |  |  | (449 | ) |  | (1,969 | )
Other unallocated |  | — |  |  | — |  |  | (156 | ) |  | (206 | )
|  | $ | 13,168 |  |  | $ | 13,045 |  |  | $ | 3,585 |  |  | $ | 1,604 |
|  | Nine Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | October 1, 2017 |  |  | October 2, 2016 |
Reportable Segments: |  |  |  |  |  |  |  |
IH |  | $ | 23,204 |  |  | $ | 21,471 |  |  | $ | 14,190 |  |  | $ | 12,470 |
EH |  | 15,639 |  |  | 17,725 |  |  | 8,558 |  |  | 9,985 |
Total reportable segments |  | 38,843 |  |  | 39,196 |  |  | 22,748 |  |  | 22,454 |
Other business activities(b), (c) |  | — |  |  | — |  |  | (2,205 | ) |  | (2,096 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate(c) |  | — |  |  | — |  |  | (3,948 | ) |  | (4,217 | )
Purchase accounting adjustments(c) |  | — |  |  | — |  |  | (3,527 | ) |  | (3,103 | )
Acquisition-related costs(c) |  | — |  |  | — |  |  | (347 | ) |  | (598 | )
Certain significant items(d) |  | — |  |  | — |  |  | (797 | ) |  | (4,112 | )
Other unallocated |  | — |  |  | — |  |  | (573 | ) |  | (753 | )
|  | $ | 38,843 |  |  | $ | 39,196 |  |  | $ | 11,351 |  |  | $ | 7,575 |
(a) | Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million, respectively, from our investment in ViiV. For additional information, see Note 4.
(b) | Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $33 million and $94 million of costs from Other Business Activities to Corporate in the third quarter and first nine months of 2016, respectively, to conform to the current period presentation.
(c) | For a description, see the “Other Costs and Business Activities” section above.
(d) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in the third quarter of 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $90 million, (ii) charges for certain legal matters of $183 million, (iii) income of $12 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $45 million. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million, (ii) income for certain legal matters of $40 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion, (iv) certain asset impairment charges of $126 million, (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million. For additional information, see Note 3 and Note 4. For Earnings in the first nine months of 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $253 million, (ii) charges for certain legal matters of $191 million, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $52 million, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $54 million and (vi) other charges of $119 million. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million, (ii) charges for certain legal matters of $506 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion, (iv) certain asset impairment charges of $1.1 billion, (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million. For additional information, see Note 3 and Note 4.
Schedule of Revenues by Geographic Region |
The following table provides revenues by geographic area:
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | % Change |  |  | October 1, 2017 |  |  | October 2, 2016 |  |  | % Change |
U.S. |  | $ | 6,534 |  |  | $ | 6,530 |  |  | — |  |  | $ | 19,516 |  |  | $ | 19,561 |  |  | — |
Developed Europe(a) |  | 2,163 |  |  | 2,218 |  |  | (2 | ) |  | 6,309 |  |  | 6,982 |  |  | (10 | )
Developed Rest of World(b) |  | 1,632 |  |  | 1,711 |  |  | (5 | ) |  | 4,797 |  |  | 4,940 |  |  | (3 | )
Emerging Markets(c) |  | 2,839 |  |  | 2,586 |  |  | 10 |  |  | 8,222 |  |  | 7,714 |  |  | 7 |
Revenues |  | $ | 13,168 |  |  | $ | 13,045 |  |  | 1 |  |  | $ | 38,843 |  |  | $ | 39,196 |  |  | (1 | )
(a) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the third quarter of 2017 and 2016, and $5.0 billion and $5.3 billion in the first nine months of 2017 and 2016, respectively.
(b) | Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
(c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.
Schedule of Significant Product Revenues |
The following table provides detailed revenue information:
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | October 1, 2017 |  |  | October 2, 2016 |
PFIZER INNOVATIVE HEALTH (IH)(a) |  | $ | 8,118 |  |  | $ | 7,332 |  |  | $ | 23,204 |  |  | $ | 21,471 |
Internal Medicine |  | $ | 2,455 |  |  | $ | 2,243 |  |  | $ | 7,245 |  |  | $ | 6,557 |
Lyrica IH(b) |  | 1,150 |  |  | 1,049 |  |  | 3,382 |  |  | 3,107 |
Eliquis alliance revenues and direct sales |  | 644 |  |  | 449 |  |  | 1,813 |  |  | 1,225 |
Chantix/Champix |  | 240 |  |  | 198 |  |  | 727 |  |  | 631 |
Viagra IH(c) |  | 206 |  |  | 297 |  |  | 711 |  |  | 897 |
BMP2 |  | 79 |  |  | 63 |  |  | 198 |  |  | 175 |
Toviaz |  | 62 |  |  | 60 |  |  | 187 |  |  | 191 |
All other Internal Medicine |  | 75 |  |  | 128 |  |  | 228 |  |  | 330 |
Vaccines |  | $ | 1,649 |  |  | $ | 1,641 |  |  | $ | 4,385 |  |  | $ | 4,576 |
Prevnar 13/Prevenar 13 |  | 1,522 |  |  | 1,536 |  |  | 4,069 |  |  | 4,302 |
FSME/IMMUN-TicoVac |  | 43 |  |  | 33 |  |  | 119 |  |  | 102 |
All other Vaccines |  | 85 |  |  | 72 |  |  | 197 |  |  | 172 |
Oncology |  | $ | 1,616 |  |  | $ | 1,104 |  |  | $ | 4,551 |  |  | $ | 3,206 |
Ibrance |  | 878 |  |  | 550 |  |  | 2,410 |  |  | 1,492 |
Sutent |  | 276 |  |  | 260 |  |  | 805 |  |  | 823 |
Xalkori |  | 146 |  |  | 140 |  |  | 442 |  |  | 415 |
Xtandi alliance revenues |  | 150 |  |  | 2 |  |  | 422 |  |  | 2 |
Inlyta |  | 84 |  |  | 95 |  |  | 256 |  |  | 304 |
Bosulif |  | 57 |  |  | 43 |  |  | 163 |  |  | 121 |
All other Oncology |  | 26 |  |  | 15 |  |  | 54 |  |  | 49 |
Inflammation & Immunology (I&I) |  | $ | 1,000 |  |  | $ | 960 |  |  | $ | 2,863 |  |  | $ | 2,907 |
Enbrel (Outside the U.S. and Canada) |  | 613 |  |  | 701 |  |  | 1,818 |  |  | 2,201 |
Xeljanz |  | 348 |  |  | 235 |  |  | 935 |  |  | 649 |
Eucrisa |  | 15 |  |  | — |  |  | 33 |  |  | — |
All other I&I |  | 23 |  |  | 24 |  |  | 78 |  |  | 57 |
Rare Disease |  | $ | 569 |  |  | $ | 585 |  |  | $ | 1,637 |  |  | $ | 1,768 |
BeneFIX |  | 151 |  |  | 176 |  |  | 453 |  |  | 543 |
Refacto AF/Xyntha |  | 140 |  |  | 140 |  |  | 409 |  |  | 408 |
Genotropin |  | 136 |  |  | 147 |  |  | 375 |  |  | 425 |
Somavert |  | 65 |  |  | 59 |  |  | 182 |  |  | 173 |
All other Rare Disease |  | 77 |  |  | 64 |  |  | 218 |  |  | 219 |
Consumer Healthcare |  | $ | 829 |  |  | $ | 798 |  |  | $ | 2,522 |  |  | $ | 2,457 |
PFIZER ESSENTIAL HEALTH (EH)(d) |  | $ | 5,050 |  |  | $ | 5,712 |  |  | $ | 15,639 |  |  | $ | 17,725 |
Legacy Established Products (LEP)(e) |  | $ | 2,681 |  |  | $ | 2,708 |  |  | $ | 7,995 |  |  | $ | 8,373 |
Lipitor |  | 491 |  |  | 422 |  |  | 1,341 |  |  | 1,294 |
Premarin family |  | 238 |  |  | 244 |  |  | 711 |  |  | 751 |
Norvasc |  | 226 |  |  | 238 |  |  | 684 |  |  | 714 |
EpiPen |  | 82 |  |  | 110 |  |  | 253 |  |  | 300 |
Xalatan/Xalacom |  | 83 |  |  | 91 |  |  | 241 |  |  | 273 |
Effexor |  | 76 |  |  | 70 |  |  | 215 |  |  | 207 |
Zoloft |  | 78 |  |  | 72 |  |  | 215 |  |  | 228 |
Zithromax |  | 61 |  |  | 56 |  |  | 202 |  |  | 203 |
Relpax |  | 50 |  |  | 83 |  |  | 193 |  |  | 248 |
Xanax |  | 58 |  |  | 55 |  |  | 164 |  |  | 163 |
All other LEP |  | 1,237 |  |  | 1,268 |  |  | 3,776 |  |  | 3,992 |
Sterile Injectable Pharmaceuticals (SIP)(f) |  | $ | 1,273 |  |  | $ | 1,461 |  |  | $ | 4,270 |  |  | $ | 4,481 |
Medrol |  | 109 |  |  | 102 |  |  | 352 |  |  | 330 |
Sulperazon |  | 114 |  |  | 102 |  |  | 345 |  |  | 304 |
Fragmin |  | 79 |  |  | 80 |  |  | 221 |  |  | 240 |
Tygacil |  | 60 |  |  | 69 |  |  | 192 |  |  | 203 |
Precedex |  | 51 |  |  | 64 |  |  | 182 |  |  | 199 |
All other SIP |  | 860 |  |  | 1,044 |  |  | 2,977 |  |  | 3,206 |
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS OF DOLLARS) |  | October 1, 2017 |  |  | October 2, 2016 |  |  | October 1, 2017 |  |  | October 2, 2016 |
Peri-LOE Products(g) |  | $ | 794 |  |  | $ | 1,023 |  |  | $ | 2,398 |  |  | $ | 3,224 |
Celebrex |  | 212 |  |  | 194 |  |  | 564 |  |  | 550 |
Lyrica EH(b) |  | 134 |  |  | 191 |  |  | 428 |  |  | 623 |
Vfend |  | 97 |  |  | 140 |  |  | 305 |  |  | 459 |
Viagra EH(c) |  | 102 |  |  | 89 |  |  | 285 |  |  | 286 |
Pristiq |  | 69 |  |  | 174 |  |  | 230 |  |  | 546 |
Zyvox |  | 68 |  |  | 94 |  |  | 220 |  |  | 334 |
Revatio |  | 58 |  |  | 73 |  |  | 189 |  |  | 213 |
All other Peri-LOE Products |  | 55 |  |  | 68 |  |  | 176 |  |  | 214 |
Biosimilars(h) |  | $ | 141 |  |  | $ | 83 |  |  | $ | 367 |  |  | $ | 228 |
Inflectra/Remsima |  | 112 |  |  | 49 |  |  | 284 |  |  | 130 |
All other Biosimilars |  | 28 |  |  | 34 |  |  | 82 |  |  | 97 |
Pfizer CentreOne(i) |  | $ | 161 |  |  | $ | 156 |  |  | $ | 514 |  |  | $ | 540 |
Hospira Infusion Systems (HIS)(j) |  | $ | — |  |  | $ | 281 |  |  | $ | 97 |  |  | $ | 879 |
Revenues |  | $ | 13,168 |  |  | $ | 13,045 |  |  | $ | 38,843 |  |  | $ | 39,196 |
Total Lyrica(b) |  | $ | 1,285 |  |  | $ | 1,240 |  |  | $ | 3,810 |  |  | $ | 3,730 |
Total Viagra(c) |  | $ | 308 |  |  | $ | 387 |  |  | $ | 996 |  |  | $ | 1,183 |
Total Alliance revenues |  | $ | 741 |  |  | $ | 419 |  |  | $ | 2,112 |  |  | $ | 1,155 |
(a) | The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
(b) | Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
(c) | Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
(d) | The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.
(e) | Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.
(f) | Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
(g) | Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.
(h) | Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
(i) | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.
(j) HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration